Antibodies Against VCAM-1 and Their Role in Cell Interaction
Author Information
Author(s): Binura Perera, Yuao Wu, Jessica R. Pickett, Nadya Panagides, Francisca M. Barretto, Christian Fercher, David P. Sester, Martina L. Jones, Hang T. Ta, Lucia F. Zacchi
Primary Institution: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland
Hypothesis
The specific functions of individual VCAM-1 Ig-like domains remain poorly understood.
Conclusion
The study identifies antibodies that target VCAM-1 domains 2 and 3, which can block macrophage adhesion to endothelial cells.
Supporting Evidence
- VCAM-1 is critical for leukocyte recruitment during inflammation.
- Antibodies against VCAM-1 have been developed for therapeutic applications.
- Blocking VCAM-1 can reduce macrophage attachment to endothelial cells.
Takeaway
Researchers found that certain antibodies can stop immune cells from sticking to blood vessel walls, which could help in treating diseases like cancer and inflammation.
Methodology
The study used phage display biopanning to identify scFv antibodies against VCAM-1 and tested their ability to block macrophage adhesion.
Limitations
The study does not explore the long-term effects of antibody treatment or its efficacy in vivo.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website